Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

Pharmacogenomics Journal

Volumn 15, Issue 1, 2015, Pages 84-94

  Saladores, P ^a,b   Murdter T ^a,b   Eccles, D ^c,d   Chowbay, B ^e,f,g   Zgheib, N K ^h   Winter, S ^a,b   Ganchev, B ^a,b   Eccles, B ^c,d   Gerty, S ^c,d   Tfayli, A ⁱ   Lim, J S L ^e   Yap, Y S ^j   Ng, R C H ^j   Wong, N S ^j   Dent, R ^j   Habbal, M Z ^h   Schaeffeler, E ^a,b   Eichelbaum, M ^a,b   Schroth, W ^a,b   Schwab, M ^a,k,l   Brauch, H ^a,b,l   more..

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e Humphrey Oei Institute of Cancer Research   (Singapore)

^f Academy of Medicine Singapore   (Singapore)

^g Singapore Health Services   (Singapore)

^h AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

ⁱ Laboratory of Professor Loiselet   (Lebanon)

^j DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; DRUG METABOLITE; ENDOXIFEN; NORENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CORRELATIONAL STUDY; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FEMALE; GENE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACOGENETICS; PREMENOPAUSE; RECURRENCE FREE SURVIVAL; BLOOD; BREAST NEOPLASMS; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921883295     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.34     Document Type: Article

References (61)

1. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel) 2011; 6: 136-141.
2. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-629.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
4. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816.
5. Gray R, Rea D, Handley K, Bowden SJ, Perry P, Earl HM et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31: 6s (supplement abstract 5).
6. Bowles EJA, Buist DSM, Chubak J, Yu O, Johnson J, Chestnut J et al. Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size. J Oncol Pract 2012; 8: 113-120.
7. Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 2012; 132: 1107-1118.
8. Ruddy KJ, Desantis SD, Gelman RS, Wu AHB, Punglia RS, Mayer EL et al. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat 2013; 141: 421-427.
9. Johnson MD, Zuo H, Lee K-H, Trebley JP, Rae JM, Weatherman RV et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151-159.
10. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyltamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55: 471-478.
11. Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009; 55: 1770-1782.
12. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-1075.
13. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-717.
14. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-725.
15. Irvin JrWJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 3232-3239.
16. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
17. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17: 93-101.
18. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al. Association Between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
19. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19: 500-507.
20. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 2013; 95: 216-227.
21. Ratain MJ, Nakamura Y, Cox NJ. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther 2013; 94: 185-187.
22. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-180.
23. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-451.
24. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460.
25. Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in postmenopausal women with early breast cancer. Br J Clin Pharmacol 2013; 77: 695-703.
26. Rae JM. CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients. Clin Pharmacol Ther 2013; 94: 183-185.
27. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010; 12: R64.
28. DezentjéVO, van Schaik RHN, Vletter-Bogaartz JM, van der Straaten T, Wessels JAM, Kranenbarg EM-K et al. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat 2013; 140: 363-373.
29. Maximov PY, McDaniel RE, Jordan VC. Tamoxifen Pioneering Medicine In Breast Cancer. Springer: Basel: New York, 2013.
30. Maximov PY, McDaniel RE, Fernandes DJ, Korostyshevskiy VR, Bhatta P et al. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. Br J Pharmacol (in press).
31. Lim JSL, Chen XA, Singh O, Yap YS, Ng RCH, Wong NS et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 2011; 71: 737-750.
32. Awada Z, Haider S, Tfayli A, Bazarbachi A, Saghir NE, Salem Z et al. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS 2013; 17: 353-367.
33. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman D et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer 2007; 7: 160.
34. Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. J Natl Cancer Inst 2013; 105: 978-988.
35. McCague R, Leclercq G, Jordan VC. Nonisomerizable analogues of (Z)- and (E)-4- hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. J Med Chem 1988; 31: 1285-1290.
36. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76: 536-544.
37. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
38. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010; 16: 4468-4477.
39. Love RR, Desta Z, Flockhart D, Skaar T, Ogburn ET, Ramamoorthy A et al. CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. Springerplus 2013; 2: 52.
40. Chlebowski RT, Kim JS, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila) 2014; 7: 378-387.
41. McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 2013; 109: 1172-1180.
42. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013; 108: 1515-1524.
43. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126: 529-537.
44. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-4128.
45. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 2004; 369: 23-37.
46. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54: 157-167.
47. Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2012; 133: 99-109.
48. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009; 10: 825-833.
49. Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 2003; 86: 255-263.
50. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28: 1287-1293.
51. Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 2010; 20: 565-568.
52. Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and longterm tamoxifen. Cancer Res 1988; 48: 1026-1029.
53. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during longterm adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991; 83: 1488-1491.
54. Gaedigk A, Bradford LD, Alander SW, Leeder JS. Cyp2d6∗36 gene arrangements within the Cyp2d6 locus: association of Cyp2d6∗36 with poor metabolizer status. Drug Metab Dispos 2006; 34: 563-569.
55. Saladores PH, Schroth W, Eccles D, Tapper W, Gerty S, Brauch HB. Abstract 2671: CYP2D6 polymorphisms are not associated with tamoxifen outcome in premenopausal women with ER positive breast cancer of the POSH cohort. Cancer Res 2012; 72: 2671-2671.
56. Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 2012; 131: 137-145.
57. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011; 90: 605-611.
58. Dickschen K, Eissing T, Mürdter T, Schwab M, Willmann S. Overcoming CYP2D6- mediated tamoxifen resistance: phenotype-specific tamoxifen-endoxifen combinations. Breast 2013; 22: S86.
59. Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC et al. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 2010; 88: 814-817.
60. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast 2013; 22: 1094-1100.
61. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118.